ArticleExperimental brain research2025
Pericyte loss: a key factor inducing brain Aβ40 accumulation and neuronal degeneration in cerebral amyloid angiopathy.
Article in Experimental brain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Endothelial Cell-Pericyte Crosstalk in the Brain Balances Microvascular Stability and Plasticity.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- [Sulforaphane reduces reactive astrocyte-mediated neuron apoptosisNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Modeling Alzheimer's disease with brain organoids: mechanisms, applications, and future directions.Frontiers in cell and developmental biology · 2026Review
- Neurovascular dysfunction in the development and progression of neuroinflammatory diseases.Frontiers in cellular neuroscience · 2026Review
- Neurovascular Dysfunction and Glymphatic Impairment: An Unexplored Therapeutic Frontier in Neurodegeneration.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cerebral amyloid angiopathy (CAA) is a cerebral small vessel disease common among the elderly. Pericyte loss is one of the earliest characteristics of CAA. Although pericyte loss correlates with neuronal loss, the molecular mechanisms by which pericyte loss contributes to neurodegeneration and CAA progression remain poorly understood. This study aimed to explore the role and the mechanism of pericyte loss in CAA using in vivo APP/PS1 mice models and an in vitro neurovascular unit (NVU) model. The findings showed that pericyte coverage and mRNA expression levels of pleiotrophin (PTN) were significantly decreased in the brain of APP/PS1 mice compared with wild-type (WT) littermate mice, while the amyloid-beta peptide (Aβ) load was elevated. Both pericyte loss and Aβ40 fibrils increased the permeability of the blood-brain barrier (BBB) and decreased secretion of PTN in the in vitro NVU model. Notably, pericyte reintroduction attenuated Aβ40-induced apoptosis in all SH-SY5Y neuroblastoma cells across experimental models, and pericytes reversed the apoptosis of SH-SY5Y cells induced by Aβ40 fibrils in these models. Furthermore, Aβ40 fibrils downregulated PTN secretion and induced pericyte apoptosis through activation of the p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. Collectively, these data suggest that BBB disruption resulting from pericyte loss serves as an early pathological hallmark in CAA, promoting Aβ40 accumulation and neurodegeneration via MAPK-dependent pathways. These findings highlight the therapeutic potential of pericyte preservation strategies in CAA management.
Indexed as
Identifiers
40748498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.